Association of Plasma Creatinine Phosphokinase Elevation and a History of Idiopathic Cardiomyopathy in Recipients of Heart Transplant

Plasma creatinine phosphokinase (CPK) elevation is frequent after heart transplantation. In the present study, we tested the hypothesis that this CPK elevation is related to idiopathic cardiomyopathy as primary cardiac disease. We included 203 patients who survived >1 year after heart transplantation. Plasma CPK was measured every 4 months during a 15.1 ± 7.7-year follow-up. In univariate analysis, CPK elevation was significantly associated with age at transplantation, length of follow-up, treatment with everolimus, and idiopathic cardiomyopathy as primary cardiac disease. In multivariate analysis, idiopathic cardiomyopathy and length of follow-up were the only significant predictors of CPK elevation (p = 0.002 and p = 0.0001, respectively). A subgroup of 19 patients had frequent CPK elevation (>20% of the dosages). All these patients but 1 had an idiopathic cardiomyopathy as primary disease. In 5 of these 19 patients, we identified a syndrome known to affect both cardiac and skeletal muscles. In conclusion, underlying idiopathic cardiomyopathy is a major determinant of plasma CPK elevation after heart transplantation. Our results show that besides well-described syndromes associating skeletal and cardiac muscle disease, idiopathic cardiomyopathy may be associated with subclinical skeletal muscle myopathy.

Infective endocarditis with neurological complications: Delaying cardiac surgery is associated with worse outcome

BACKGROUND

Infective endocarditis (IE) is associated with a high mortality rate, related in part to neurological complications. Studies suggest that valvular surgery should be performed early when indicated, but is often delayed by the presence of neurological complications.

AIM

To assess the effect of delaying surgery in patients with IE and neurological complications and to identify factors predictive of death.

METHODS

In a prospective, single-centre study in a referral centre for IE, all patients with IE underwent systematic screening for neurological complications. The primary outcome was 6-month death. In patients presenting with neurological complications, the prognosis according to surgical status was analysed and a Cox regression model used to identify variables predictive of death.

RESULTS

Between April 2014 and January 2018, 351 patients with a definite diagnosis of left-sided IE were included. Ninety-four patients (26.8%) presented with at least one neurological complication. Fifty-nine patients (17.7%) died during 6-month follow-up. Six-month mortality rates did not differ significantly between patients with and without neurological complications (P=0.60). Forty patients had a temporary surgical contraindication because of neurological complications. During the period of surgical contraindication, seven of these patients (17.5%) died, six (15.0%) presented a new embolic event, and 12 (30.0%) presented cardiac or septic deterioration. In multivariable analysis, predictive factors of death in patients presenting with neurological complications were temporary surgical contraindication (hazard ratio 7.36, 95% confidence interval 1.61-33.67; P=0.010) and presence of a mechanical prosthetic valve (hazard ratio 16.40, 95% confidence interval 2.22-121.17; P=0.006).

CONCLUSIONS

Patients with a temporary surgical contraindication due to neurological complications had a higher risk of death and frequent major complications while waiting for surgery. When indicated, the decision to postpone surgery in the early phase should be weighed against the risk of infectious or cardiac deterioration.

Infective endocarditis in patients with heart transplantation

BACKGROUND

The incidence of nosocomial and health care-related infective endocarditis (IE) is increasing. Heart transplantation (HT) implies immunosuppression and frequent health care contact. Our aim was to describe the current profile and prognosis of IE in HT recipients.

METHODS

Multicenter retrospective registry-based study in Spain and France that included cases between 2008 and 2019.

RESULTS

During the study period, 8305 HT were performed in Spain and France. We identified 18 IE cases (rate 0.2%). Median age was 57 years; 12 were men (67%). Valve involvement did not have a predominant location and three patients (16.7%) had atrial or ventricular vegetations without valve involvement. The median age-adjusted Charlson index was 4 (interquartile range 3-5). Eleven IE cases (61%) were nosocomial/health care-related. Median time (range) between HT and development of IE was 43 months (interquartile range 6-104). The major pathogens were Staphylococcus sp. (n = 8, 44%), Enterococcus sp. (n = 4, 22%), and Aspergillus sp. (n = 3, 17%). Although eight patients (44%) had a surgical indication, it was only performed in three cases (17%). Three patients (17%) died during the first IE hospital admission.

CONCLUSIONS

IE in HT recipients has specific characteristics. Valve involvement does not have a predominant location and non-valvular involvement is common. Three fifths have a nosocomial/health care-related origin. The major pathogens were staphylococci (44%), enterococci (22%), and Aspergillus (17%). In-hospital mortality was 17%.

Left atrial dysfunction as marker of poor outcome in patients with hypertrophic cardiomyopathy

BACKGROUND

The incremental prognostic value of left atrial (LA) dysfunction, emerging in various clinical contexts, remains poorly explored in hypertrophic cardiomyopathy (HCM).

OBJECTIVE

To assess LA strain correlation with outcome in HCM.

METHODS

A cohort of all 307 consecutive patients presenting with HCM between 2007 and 2017 (54±17 years; 34% women), with comprehensive echocardiography at diagnosis and LA peak longitudinal strain (PALS) and LA peak contraction strain (PACS) measurement, was enrolled and occurrence of HCM related cardiac events analysed.

RESULTS

Clinically, atrial fibrillation (AF) was present in 13%, New York Heart Association functional class II-III in 54%, and B-type natriuretic peptide (BNP) concentration was 199±278pg/mL. By echocardiography, left ventricular (LV) ejection fraction (EF) was 67±10%, LV thickness 21±5mm and European Society of Cardiology HCM risk score 3±3%, with 109 patients (36%) presenting obstructive HCM (LV outflow gradient 21±32mmHg). LA diameter was 41±8mm [with 109 (36%) presenting LA diameter ≥40mm], LA volume index 50±26mL/m², PALS 24±13%, PACS 11±7% and LA peak systolic strain rate (LASRs) 1.7±0.6 s^-1. In addition to AF, age, BNP, LVEF and LV thickness were all independent determinants of lower PALS, with odd ratios almost unchanged after adjustment (all P ≤0.0004). At a mean follow-up of 21 (range 18-23) months, patients with adverse cardiac events (n=65) presented with more impaired LA function (all P ≤0.0005), with a significant association between impaired PALS and worse outcome, hazard ratio 0.94 [95% confidence interval (CI) 0.92-0.97, P<0.0001]. After comprehensive adjustment, PALS remained strongly associated with worse outcome, adjusted hazard ratio 0.86 (95% CI 0.79-0.94; P=0.0008).

CONCLUSIONS

The present study, by gathering a unique HCM cohort, suggests a strong link between LA dysfunction and poor outcome, to be further investigated.

Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo

BACKGROUND AND OBJECTIVES

The value of glycosylated hemoglobin (HbA1c) as a surrogate marker for the prevention of cardiovascular outcomes on antidiabetic drugs is debated. The 2008 FDA guidance led to multiple large clinical trials to evaluate the effect of new antidiabetic drugs versus placebo on major adverse cardiac events (MACE). The aim of this study was to evaluate the relation between MACE and HbA1c decrease between antidiabetic drug and placebo across the spectrum of cardiovascular outcome trials (CVOT).

METHODS

In this systematic review, we included randomized controlled trials that compared an antidiabetic drug to placebo in addition to current standard of care with the primary intention of demonstrating cardiovascular safety. We investigated the relationship between MACE decrease on antidiabetic drug and HbA1c reduction on antidiabetic drug using the coefficient correlation. We also studied the effects of potential confounders on MACE decrease.

RESULTS

Fourteen eligible trials including 128,149 patients were included, 12,114 of whom experienced MACE. Mean achieved HbA1c absolute reductions on antidiabetic treatment versus placebo varied from 0.29 to 1%. The decrease of MACE on antidiabetic drug was significantly correlated with mean HbA1c reduction (r = 0.88, 95% CI: 0.67-0.96, p < 0.001) and weight loss (r = 0.81, 95% CI: 0.46-0.94, p < 0.001). In a bivariate model including weight loss, only HbA1c reduction remained significantly correlated with the decrease of MACE on antidiabetic drug (p = 0.019).

CONCLUSION

Across CVOT, the decrease in MACE incidence on various antidiabetic drugs is significantly correlated with HbA1c reduction. This meta-analysis supports HbA1c as an appropriate surrogate endpoint for cardiovascular events. Our analysis supports that changes in HbA1c should be taken into account while interpreting effects of new antidiabetic drugs on cardiovascular outcomes.

Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies

BACKGROUND

An accurate estimation of the risk of life-threatening (LT) ventricular tachyarrhythmia (VTA) in patients with LMNA mutations is crucial to select candidates for implantable cardioverter-defibrillator implantation.

METHODS

We included 839 adult patients with LMNA mutations, including 660 from a French nationwide registry in the development sample, and 179 from other countries, referred to 5 tertiary centers for cardiomyopathies, in the validation sample. LTVTA was defined as (1) sudden cardiac death or (2) implantable cardioverter defibrillator-treated or hemodynamically unstable VTA. The prognostic model was derived using the Fine-Gray regression model. The net reclassification was compared with current clinical practice guidelines. The results are presented as means (SD) or medians [interquartile range].

RESULTS

We included 444 patients, 40.6 (14.1) years of age, in the derivation sample and 145 patients, 38.2 (15.0) years, in the validation sample, of whom 86 (19.3%) and 34 (23.4%) experienced LTVTA over 3.6 [1.0-7.2] and 5.1 [2.0-9.3] years of follow-up, respectively. Predictors of LTVTA in the derivation sample were: male sex, nonmissense LMNA mutation, first degree and higher atrioventricular block, nonsustained ventricular tachycardia, and left ventricular ejection fraction (https://lmna-risk-vta.fr). In the derivation sample, C-index (95% CI) of the model was 0.776 (0.711-0.842), and the calibration slope 0.827. In the external validation sample, the C-index was 0.800 (0.642-0.959), and the calibration slope was 1.082 (95% CI, 0.643-1.522). A 5-year estimated risk threshold ≥7% predicted 96.2% of LTVTA and net reclassified 28.8% of patients with LTVTA in comparison with the guidelines-based approach.

CONCLUSIONS

In comparison with the current standard of care, this risk prediction model for LTVTA in laminopathies significantly facilitated the choice of candidates for implantable cardioverter defibrillators.

CLINICAL TRIAL REGISTRATION

URL: https://www.clinicaltrials.gov. Unique identifier: NCT03058185.

Rapid Isolation of Human Endothelial Cells from Whole Blood Using S-Endo1 Monoclonal Antibody Coupled to Immuno-Magnetic Beads: Demonstration of Endothelial Injury after Angioplasty

The presence in whole blood of circulating endothelial cells (EC) has been a subject of debate for many years. It could represent a good marker of vessel injury. We demonstrate here that human endothelial cells can be directly isolated and identified in circulating blood by means of an endothelial cell specific monoclonal antibody, S-Endol, coupled to micromagnetic beads. The specificity and efficacy of the assay were established using normal blood samples with cultured EC added. Specific rosettes formed between EC and beads could subsequently be isolated with a magnet. The rosetted cells were recovered with a yield >80%. Their endothelial origin was confirmed by the positive labelling of von Willebrand factor and thrombomodulin, as well as the presence of Weibel-Palade bodies. We applied this method to demonstrate significantly increased levels of EC in venous and arterial human blood samples in patients undergoing heart catheterization. This new whole blood immuno-separation method may be useful in determining endothelial cell injury in vascular disorders.

Fluvastatin Decreases Soluble Thrombomodulin in Cardiac Transplant Recipients

We conducted a randomized, placebo controlled, double-blind, cross-over study, to assess the effects of a 4-week fluvastatin therapy on plasma markers of endothelial activation or injury in 20 transplanted heart recipients. The levels of thrombomodulin and von Willebrand factor antigen were higher at baseline in cardiac transplant recipients than in age and sex-matched healthy controls. Plasma total cholesterol showed a 21% reduction on fluvastatin therapy (p = 0.0001). Fluvastatin treatment had no significant effect on creatininemia, plasma cyclosporine, PAI-1 antigen, PAI-1 activity, tPA antigen, and Von Willebrand factor. However, fluvastatin produced a significant decrease of plasma thrombomodulin (66.7 ng/ml on placebo versus 58.8 ng/ml on fluvastatin, p <0.001), suggesting a rapid improvement of endothelial injury in these patients.

EVOLUTION OF THE IEC AND EN STANDARDS FOR INDIVIDUAL MONITORING OF IONISING RADIATION

This article presents the evolution of the International Electrotechnical Commission (IEC) and the European standards for individual monitoring of ionising radiation issued, respectively, from the committees IEC/Sub Committee 45B and European Committee for Electro-technical Standardization/Technical Committee 45B 'Radiation protection instrumentation'. Standards for passive individual photon and beta dosimetry systems as well as those for active individual monitors are discussed. A neutron ambient dose equivalent (rate) meter standard and a technical report concerning the determination of uncertainty in measurement are also covered.

Implications of X-ray tube parameter deviations in X-ray reference fields

For the purpose of radiation protection, ICRU Report 57/ICRP Publication 74 provides a list of monoenergetic conversion coefficients to be used with, among others, photon reference fields generated with X-ray tubes. A comprehensive definition of these photon reference fields can be found in international standard ISO 4037; however, it lacks thorough indication of the allowed deviations of essential parameters that influence these X-ray reference fields. These parameters are the high-voltage tube potential, the thickness of the beryllium window and the purity and thickness of the filter materials used to create different radiation qualities. Small variations of these parameters can lead to significant changes in the created X-ray spectra and, hence, the spectra-dependent conversion coefficients for phantom-related radiation-protection quantities. This can lead to situations in which the conversion coefficients listed in ISO 4037 cannot be used, resulting in time-consuming spectrometry measurements. In this work, the impact on the resulting conversion coefficients is investigated using a simplified mathematical approximation model. The findings are validated with an independent X-ray spectra calculation programme. As a result, well-founded upper limit values on the allowed deviations of the essential X-ray tube parameters are proposed to be used in a future revision of ISO 4037.

Determination of relevant parameters for the use of electronic dosemeters in pulsed fields of ionising radiation

Active electronic dosemeters using counting techniques are used for radioprotection purposes in pulsed radiation fields in X-ray diagnostics or therapy. The disadvantage of the limited maximum measurable dose rate becomes significant in these radiation fields and leads to some negative effects. In this study, a set of relevant parameters for a dosemeter is described, which can be used to decide whether it is applicable in a given radiation field or not. The determination of these relevant parameters-maximum measurable dose rate in the radiation pulse, dead time of the dosemeter, indication per counting event and measurement cycle time-is specified. The results of the first measurements on the determination of these parameters for an electronic personal dosemeter of the type Thermo Fisher Scientific EPD Mk2 are shown.

IEC standards for individual monitoring of ionising radiation

This paper presents IEC/SC 45B 'Radiation protection instrumentation' and its standards for individual monitoring of ionising radiation: IEC 61526 Ed. 3 for active personal dosemeters and IEC 62387-1 for passive integrating dosimetry systems. The transposition of these standards as CENELEC (European) standards is also discussed together with the collaboration between IEC/SC 45B and ISO/TC 85/SC 2.

The new EC technical recommendations for monitoring individuals occupationally exposed to external radiation

The purpose of the European Commission technical recommendations (TR) for monitoring individuals occupationally exposed to external radiation is to provide guidance on those aspects of the implementation of the European Union Parliament and Council Directives directly related to individual monitoring of external radiation, and to encourage harmonisation thereof. They are mainly aimed at the management and staff of IM services but also at manufacturers, laboratories supplying type-testing services, national authorities trying to harmonise approval procedures, and government bodies to harmonise regulations and guidance. The TR main topics are: objectives and aims of IM for external radiation; dosimetry concepts; accuracy requirements; calibration, type testing and performance testing; approval procedures; quality assurance and quality control; and dose record keeping. Attention is paid to particular aspects, such as wide energy ranges for the use of personal dosemeters, pulsed fields and non-charged particle equilibrium; and use of active personal dosemeters. The TR give proposals towards achieving harmonisation in IM and the eventual mutual recognition of services and of dose results.

Influence of the uniformity of the slab phantom illumination on the calibration of personal dosemeters

For the calibration of personal dosemeters in terms of H(p)(10), the ISO water slab phantom shall be used. The irradiation geometry must be chosen such that the field diameter at the phantom front surface is large enough to irradiate the phantom completely and, in addition, homogeneously. However, in practice it is not always possible to achieve this, especially if high dose rates are required and hence the irradiation must be performed at short distances. The subject of this investigation is to determine the influence of the beam diameter on the calibration result or, more correctly, on the quantity value of H(p)(10). Measurements were performed with a PTB-developed secondary standard chamber for H(p)(10) at several radiation qualities of the ISO narrow-spectrum series. The results show that a reduced beam diameter of only 250 mm decreases the quantity value of H(p)(10) by a maximum of 5 %. This can be considered by adding an additional standard uncertainty of a maximum of 5 % for the quantity value of H(p)(10).

Deficiencies of active electronic radiation protection dosimeters in pulsed fields

Nowadays nearly all radiation fields used for X-ray diagnostics are pulsed. These fields are characterised by a high dose rate during the pulse and a short pulse duration in the range of a few milliseconds. The use of active electronic dosimeters has increased in the past few years, but these types of dosimeters might possibly not measure reliably in pulsed radiation fields. Not only personal dosimeters but also area dosimeters that are used mainly for dose rate measurements are concerned. These cannot be substituted by using passive dosimeter types. The characteristics of active electronic dosimeters determined in a continuous radiation field cannot be transferred to those in pulsed fields. Some provisional measurements with typical electronic dosimeters in pulsed radiation fields are presented to reveal this basic problem.

Correlation of NT-proBNP with diastolic left ventricular function in elderly patients with ischemic stroke

We tested the hypothesis that, in elderly survivors of ischemic stroke, high NT-proBNP levels are related with frequent diastolic dysfunction. We prospectively measured NT-proBNP, left ventricular ejection fraction (LVEF) and echographic parameters of diastolic function in 55 elderly consecutive patients, 6.8+/-2.6 days after acute ischemic stroke. We found that all the patients had systolic or diastolic dysfunction (14 had LVEF<50%, 26 mild diastolic dysfunction+LVEF > or = 50%, and 15 moderate or severe diastolic dysfunction+LVEF > or = 50%). The most powerful predictors of NT-proBNP were LVEF (R=0.38, p=0.004) and ratio of mitral E to the early diastolic velocity of the mitral annulus:E/E'(R=0.34, p=0.01).

Comparison of B-type natriuretic peptide with left atrial enlargement by echocardiography for the diagnosis of new-onset congestive heart failure with a preserved left ventricular systolic function in the setting of longstanding hypertension

The present study attempted to determine the accuracy of B-type natriuretic peptide (BNP) compared with left atrial enlargement at echocardiography in the emergency diagnosis of new-onset heart failure with preserved systolic function (HFPSF) related to longstanding hypertension. The study comprised 57 patients in sinus rhythm hospitalized for acute dyspnea, 30 with hypertensive HFPSF and 27 with noncardiac cause. By stepwise logistic regression analysis, BNP provided independent and incremental diagnostic information over the score of Boston criteria. There was a trend toward superiority of this biomarker compared to the left atrial area index for the diagnosis of HFPSF. A BNP concentration >142 pg/ml was 93% sensitive and 85% specific for the diagnosis of HFPSF in this clinical setting (area under the ROC curve of 0.91 [0.8-0.97], p<0.001).

New concept of IEC standards for radiation protection dosemeters

The International Electrotechnical Commission (IEC) develops new standards for radiation protection dosemeters which follow a new concept. They are much more flexible in detail, but still ensure the same measurement quality. They are, for example, no longer specific for the detector type, but rather specific for the measurement task, e.g. for individual monitoring with active direct-reading instruments. Another example is that they are flexible with respect to the ranges of influence quantities. The conceptual changes are described in this paper, together with the advantages this new concept provides for manufacturers, users and legislators.